May 13 that the Stage 2a outcomes of an oral alpha 4 integrin antagonist.

Ajinomoto announces Phase 2a outcomes of oral alpha 4 integrin antagonist AJM300 in ulcerative colitis patients Ajinomoto Pharmaceuticals Co., Ltd http://viagrauk.net/brief-review-of-the-ed-drug-suhagra.html . announced on, may 13 that the Stage 2a outcomes of an oral alpha 4 integrin antagonist, AJM300, in individuals with ulcerative colitis were provided in the Joint Presidential Plenary Program at Digestive Disease Week 2014 held Might 3 – 6 in Chicago, IL, USA.